On behalf of a major investment management firm, we conducted a privileged independent investigation into whistleblower allegations of investor harm due to cell formula errors in a valuation model, as well as subsequent allegations of retaliation. Presented findings to the board of directors and the Securities and Exchange Commission. The SEC subsequently determined not to recommend an enforcement action by the Commission against the firm.
Over $2.9 billion recovered through settlements and judgments under the False Claims Act
The False Claims Act (FCA) remains one of the most powerful tools for combating fraudulent claims in government funding, with billions recovered annually. In...